title: Enzyme kinetics of cytochrome P450-mediated reactions.
abstract: The most common drug-drug interactions may be understood in terms of alterations of metabolism, associated primarily with changes in the activity of cytochrome P450 (CYP) enzymes. Kinetic parameters such as Km, Vmax, Ki and Ka, which describe metabolism-based drug interactions, are usually determined by appropriate kinetic models and may be used to predict the pharmacokinetic consequences of exposure to one or multiple drugs. According to classic Michaelis-Menten (M-M) kinetics, one binding site models can be employed to simply interpret inhibition (pure competitive, non-competitive and uncompetitive) or activation of the enzyme. However, some cytochromes P450, in particular CYP3A4, exhibit unusual kinetic characteristics. In this instance, the changes in apparent kinetic constants in the presence of inhibitor or activator or second substrate do not obey the rules of M-M kinetics, and the resulting kinetics are not straightforward and hamper mechanistic interpretation of the interaction in question. These unusual kinetics include substrate activation (autoactivation), substrate inhibition, partial inhibition, activation, differential kinetics and others. To address this problem, several kinetic models can be proposed, based upon the assumption that multiple substrate binding sites exist at the active site of a particular P450, and the resulting kinetic constants are, therefore, solved to adequately describe the observed interaction between multiple drugs. The following is an overview of some cytochrome P450-mediated classic and atypical enzyme kinetics, and the associated kinetic models. Applications of these kinetic models can provide some new insights into the mechanism of P450-mediated drug-drug interactions.
authors.affiliation: Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA. magang_shou@merck.com
authors.forename: M
authors.initials: M
authors.lastname: Shou
authors.forename: Y
authors.initials: Y
authors.lastname: Lin
authors.forename: P
authors.initials: P
authors.lastname: Lu
authors.forename: C
authors.initials: C
authors.lastname: Tang
authors.forename: Q
authors.initials: Q
authors.lastname: Mei
authors.forename: D
authors.initials: D
authors.lastname: Cui
authors.forename: W
authors.initials: W
authors.lastname: Tang
authors.forename: J S
authors.initials: JS
authors.lastname: Ngui
authors.forename: C C
authors.initials: CC
authors.lastname: Lin
authors.forename: R
authors.initials: R
authors.lastname: Singh
authors.forename: B K
authors.initials: BK
authors.lastname: Wong
authors.forename: J A
authors.initials: JA
authors.lastname: Yergey
authors.forename: J H
authors.initials: JH
authors.lastname: Lin
authors.forename: P G
authors.initials: PG
authors.lastname: Pearson
authors.forename: T A
authors.initials: TA
authors.lastname: Baillie
authors.forename: A D
authors.initials: AD
authors.lastname: Rodrigues
authors.forename: T H
authors.initials: TH
authors.lastname: Rushmore
mesh_terms: D000465:Algorithms; D000818:Animals; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004789:Enzyme Activation / Q000502:physiology; D006801:Humans; D007700:Kinetics
chemical_list: D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System